MAV reported Q2 2023 sales of €20.7 million, a 19% decrease compared to the prior year, primarily due to distribution losses in U.S. Mass and drug channels, despite strong e-commerce growth and Canadian market performance.
Gross profit decreased by 13% to €9.3 million, with a gross profit margin improvement to 45.1% from 42.4%, aided by €595,000 in business interruption insurance proceeds.
Adjusted EBITDA declined to €2.7 million from €3.5 million in Q2 2022, while free cash flow improved to €1.9 million from €1.3 million due to reduced non-cash working capital.
The company reported a net loss of €2.2 million compared to net income of €300,000 in Q2 2022, driven by lower revenue, higher interest expenses, and costs related to a strategic review process.
MAV's cash position at quarter-end was €8.2 million, with net debt at €115.8 million, as the company continues operational improvements and innovation efforts across its brand portfolio for future growth.